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We analyzed the effects of a 4-month resistance (weight lifting) training program followed
by a 2-month detraining period in 7 adult McArdle patients (5 female) on: muscle mass
(assessed by DXA), strength, serum creatine kinase (CK) activity and clinical severity.
Adherence to training was ≥84% in all patients and no major contraindication or side effect
was noted during the training or strength assessment sessions. The training program had
a significant impact on total and lower extremities’ lean mass (P < 0.05 for the time
effect), with mean values increasing with training by +855 g (95% confidence interval (CI):
30, 1679) and +547 g (95%CI: 116, 978), respectively, and significantly decreasing with
detraining. Body fat showed no significant changes over the study period. Bench press
and half-squat performance, expressed as the highest value of average muscle power (W)
or force (N) in the concentric-repetition phase of both tests showed a consistent increase
over the 4-month training period, and decreased with detraining. Yet muscle strength and
power detraining values were significantly higher than pre-training values, indicating that
a training effect was still present after detraining. Importantly, all the participants, with no
exception, showed a clear gain in muscle strength after the 4-month training period, e.g.,
bench press: +52 W (95% CI: 13, 91); half-squat: +173 W (95% CI: 96, 251). No significant
time effect (P > 0.05) was noted for baseline or post strength assessment values of serum
CK activity, which remained essentially within the range reported in our laboratory for
McArdle patients. All the patients changed to a lower severity class with training, such
that none of them were in the highest disease severity class (3) after the intervention and,
as such, they did not have fixed muscle weakness after training. Clinical improvements
were retained, in all but one patient, after detraining, such that after detraining all patients
were classed as class 1 for disease severity.
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INTRODUCTION
There is an urgent need to improve the treatment and prevention
of aging sarcopenia as well as the muscle atrophy commonly
associated with chronic disorders. Although several pharmaco-
logical therapies have been proposed to minimize sarcopenia and
atrophy, they are not free of adverse side effects (Sanchis-Gomar
et al., 2014). Physical exercise, particularly resistance (strength)
exercise (i.e., movement, such as weight lifting or exercises with
resistance bands, performed against a specific external force that
is regularly increased during training), is an alternative approach
to reverse muscle atrophy, although it is frequently overlooked in
the clinical setting. Yet this type of exercise should form part of
the routine exercise prescription to maintain and improve health
and functional status in most, if not all population groups (Garber
et al., 2011).
McArdle disease (glycogenosis (or glycogen storage disease)
type V or myophosphorylase deficiency; OMIM® database number
232600), is an inborn disorder of skeletal-muscle carbohydrate
metabolism characterized by failure of muscle glycogen break-
down. McArdle disease is a challenging disease model in which
to study the feasibility and effects of resistance exercise in debil-
itated people: this disorder is arguably the paradigm of human
exercise intolerance and rhabdomyolysis (Lucia et al., 2008). The
latter is reflected by the efflux of intra-muscle proteins to the
bloodstream, e.g., creatine kinase (CK) and myoglobin. Thus, high
serum CK activity (typically> 1,000 U·L−1) caused by exercise is
a common finding in these patients, which can be accompanied
by myoglobinuria, typically referred to as “dark urine” (Santalla
et al., 2014). Additionally, fixed muscle weakness is an incident
problem as patients age (Santalla et al., 2014). Despite some
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studies showing the benefits of light-moderate intensity aerobic
exercise in patients with McArdle disease (Haller et al., 2006;
Maté-Muñoz et al., 2007; Perez et al., 2008), at present, clinicians
in charge of these patients discourage performance of strenu-
ous exercise, particularly resistance exercise (e.g., weight lifting),
owing to a potential increased risk of severe rhabdomyolysis,
which might eventually lead to acute renal failure in the most
severe cases (Lucia et al., 2008). Yet preliminary data from our
group indicated increases in dynamic muscle strength with no
myoglobinuria in a 14-year-old male patient with McArdle disease
in response to a 6-week, supervised light-moderate intensity
weight lifting training program (García-Benítez et al., 2013).
However, muscle mass, an important health indicator, was not
determined.
We assessed the effects of a 4-month resistance training pro-
gram followed by a 2-month detraining period in a group of adult
McArdle patients on the following outcomes: muscle mass and
strength, serum CK activity, and clinical severity.
METHODS
PATIENTS
Before entering the study, written informed consent was obtained
from each participant, and the study was approved by the local
human investigations committee and review board. Inclusion
criteria were: adult with no disease contraindicating exercise other
than McArdle disease, belonging to class severity 1–3 (Martinuzzi
et al., 2003) (see below), living in the Madrid area (or willing to
move there for the duration of the study period) to participate in
all testing and training sessions. Eight McArdle patients (5 female)
originally volunteered to participate in this study but one of them
(male) withdrew because he had to move to a different country
due to professional obligations after the first strength assessments.
Genetic diagnosis was confirmed in all patients, i.e., they harbored
documented pathogenic genotypes in the gene (PYGM) encoding
myophosphorylase (Lucia et al., 2012), as shown in Table 1 (main
demographic and clinical characteristics). All subjects reported
symptoms of exercise intolerance since childhood and 4 belonged
to the highest severity class, i.e., class 3 (that is, they had fixed
muscle weakness) (Martinuzzi et al., 2003).
DESIGN
All study outcomes were assessed in each patient at 3 time points:
before (baseline) and after the 4-month training period (“post-
training”), and after detraining. Muscle strength and serum CK
activity (see below) were also measured at the end of the 1st, 2nd
and 3rd month of the training period. Owing to the relative rare
nature of the disease (prevalence of ∼1/167,000 in Spain) (Lucia
et al., 2012), it was not possible to gather a sufficient number of
patients to conduct a randomized controlled trial. Thus, a quasi-
experimental reversal design was used, in which each subject acts
as their own control (Thomas et al., 2005).
TRAINING PROGRAM
All training sessions and strength evaluations were performed
in the same setting, i.e., in the gymnasium of the Universidad
Europea (Madrid, Spain) and were supervised by experienced
professionals (fitness instructors with a Master degree in Sports
Science, 1 instructor/patient). Two familiarization sessions were
performed by each subject, prior to starting the training program,
which included 2 weekly sessions for 4 months (total of planned
sessions = 32). A recovery period of at least 48 h was allowed
between sessions, and the vast majority of the sessions were
performed during week days. Make-up sessions were allowed
(including during weekend days) when 1 session was missed and
if fulfilling the criteria of ≥48 h of recovery between sessions.
Before each training or strength assessment session (see
below), patients performed 2 consecutive warm-up sessions of
12-minute duration each, the first on an arm-crank ergometer
and the second on a cycle-ergometer, in order to trigger the
occurrence of the “second wind” (that is, the attenuation of early
fatigue, increased risk of contractures and rhabdomyolysis that
commonly occurs after 7–8 min of dynamic exercise in these
patients (Vissing and Haller, 2003)) in both upper and lower body
muscles, respectively. The end of the warm-up was followed by
ingestion of a commercialized sports drink (330 mL, containing
∼30 g of sucrose). All training and strength assessment sessions
were followed by passive stretching exercises and hydration with
plain water. We did not perform dietary analysis but patients
were instructed to consume a high proportion (65%) of complex
Table 1 | Main characteristics of the study participants at the start of the study.
Subject Sex Age BMI PYGM Diagnostic Resting Fixed Clinical
(years) (kg·m2−) genotype corroborated by CK muscle severity
muscle biopsy∗ (U·L−1) weakness class
A Female 36 18.3 R50X/p.V456M Yes 1076 Yes 3
B Female 34 30.6 R50X/W798R Yes 3938 Yes 3
C Male 23 21.7 G205S/c.1768+1G > A No 1556 No 1
D Male 29 23.7 G205S/c.1768+1G > A Yes 2050 No 2
E Female 36 21.9 p.R50X/p.R50X Yes 1373 No 2
F Female 58 27.4 R50X/p.K754fsX49 Yes 1211 Yes 2
G Female 53 29.1 G205WS/R590H Yes 543 Yes 3
Abbreviations: BMI, body mass index. * Negative histochemical reaction for myophosphorylase and no myophosphorylase activity.
Note: Subjects C and D were brothers. Muscle fixed weakness affected mostly proximal/trunk (paraspinal, neck flexor, periscapular, proximal upper limb, axial or
shoulder girdle) muscles in a symmetric matter in patients A, B and F, whereas it affected mostly lower extremities’ muscles (also in a symmetric manner) in patient
G. See text for description of clinical severity classes.
Frontiers in Aging Neuroscience www.frontiersin.org December 2014 | Volume 6 | Article 334 | 2
Santalla et al. Resistance training in McArdle patients
Table 2 | Mean ± SEM values of body composition assessed by dual energy x-ray absorptiometry (DXA).
Outcome Pre- Post- Detraining Time Pre- vs. Pre- vs. Post- vs.
training training effect post-training detraining detraining
Lean mass
Total (g) 43,089 ± 1,997 43,944 ± 1,935 42,822 ± 2,099 P = 0.018 P = 0.043 P = 0.917 P = 0.018
Trunk (g) 21,179 ± 869 21,378 ± 833 20,928 ± 882 P = 0.772 - - -
Legs (g) 14,662 ± 825 15,209 ± 815 14,688 ± 889 P = 0.018 P = 0.043 P = 0.753 P = 0.018
Arms (g) 4,110 ± 353 4,206 ± 381 4,008 ± 398 P = 0.121 - - -
Body fat (g) 21,571 ± 2,880 21,473 ± 2,896 21,009 ± 2,625 P = 0.368 - - -
Significant P-values are in bold. Pairwise post hoc comparisons (Wilcoxon test) were only performed when a significant time effect was found.
carbohydrates (fruits, cereals, bread, pasta, rice) in the 2 meals
(breakfast and lunch) that preceded each testing or training
session (García-Benítez et al., 2013).
Except for the first 8 sessions of the program (where sets of
10 repetitions with very low loads were performed), the exercises
composing sessions were performed for sets of a low number of
repetitions (5–6) using a load (kg) eliciting a rating of perceived
exertion (RPE) of 6–7 (on a 0 (= minimum effort) to 10 (=
maximum effort) scale). Exercises were performed using a circuit
involving large muscle groups and specific weight training equip-
ment (Technogym; Gambetolla, Italy), in the following order:
bench press, leg press, pull down and abdominals. At the end of
the 1st month, the leg and bench press exercises were gradually
replaced by the half squat and bench press performed on a
“multipower” machine (Technogym; Gambetolla, Italy). The low
number of repetitions allows the use of muscle phosphocreatine
(PC) as the main energy substrate to fuel contraction, with no
major reliance on muscle glycogen deposits and the circuit struc-
ture, with 2–3-min rest periods between each set of repetitions
and exercises, was designed to allow PC to be resynthesized in a
given muscle before this muscle was utilized again.
Passive stretching exercises were performed after each set of an
exercise to attenuate muscle stiffness (3 × 30 s for each muscle
group). The load was adjusted after the 1st month and thereafter
was readjusted according to the results of the last strength assess-
ment, with the purpose of reaching peak power with a similar
number of sets (i.e., 4–6 sets for bench press and 6–8 sets for
half-squat). The rate of increase in training load was constantly
adjusted according to the patients’ RPE. Thus, when the patient
reported a RPE value of 6 for a given exercise in 2 consecutive ses-
sions, the load for this particular exercise was increased (with the
premise that RPE for the new load remained≤7). On average, the
load used for an exercise increased from the start to the end of the
training program as follows: 5.4 kg→12.8 kg (+139.7%) for chest
press; 34.9 kg→12.7 kg (+174%) for half-squat; 10.3 kg→19.2
kg (+85.9%) for pull down; and 3.9 kg→18.3 kg (+368.1%) for
abdominal muscles.
OUTCOME ASSESSMENT
After familiarization with the equipment, participants per-
formed “explosive” leg half-squats on a “Multipower machine”,
which was connected to a linear encoder (T-Force Dynamic
Measurement System, Ergotech, Murcia, Spain). The latter has
previously proven valid to determine force (N) and power (W)
FIGURE 1 | Example of strength test (bench press) performed by one of
the patients. The Figure shows that the velocity (ms−1) decreases with
increasing load (kg), while the average concentric-propulsive power initially
increases to a load in which the decrease of velocity is so pronounced that
power decreases. The highest average concentric-propulsive power of
73 W occurred at a load of 8 kg.
(González-Badillo and Sánchez-Medina, 2010). Patients per-
formed 1 set of 3 repetitions at maximum speed with a 2-min
recovery period. The load or “resistance” (kg) was increased by
2.5 kg in each successive set. Average muscle force and power
output in the concentric-propulsive phase of the repetition were
evaluated in each set (Sanchez-Medina et al., 2010). In this type of
gradual resistance increase protocol, the developed muscle force
increases with resistance, while the velocity of muscle contraction
decreases. Power is the product of force × velocity, and initially
increases with resistance and then decreases when the resistance
causes a substantial decrease in velocity. Thus, the test is stopped
when the decrease in velocity is so pronounced that it causes a
decrease in average muscle concentric power (see Figure 1 for an
example). For statistical analyses we recorded the highest value of
average power (W) in the concentric-propulsive phase, which typ-
ically coincides with the start of a decline in this variable together
with the occurrence of the highest value of average force (N). We
also recorded the load (kg) at which maximum average power was
generated. The RPE after each set never exceeded the value of 7.
Total and regional body composition was assessed by dual
energy x-ray absorptiometry (DXA; Hologic Serie Discovery
QDR, Software Physician’s Viewer, APEX System Software Version
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3.1.2. Bedford, MA, USA). Body mass composition was calculated
from whole-body scans. Whole-body scans were submitted to a
regional analysis to determine the composition of the arm, leg
and trunk regions. The arm region included the hand, forearm
and arm, and was separated from the trunk by an inclined line
crossing the scapulo-humeral joint, such that the humeral head
was located in the arm region. The leg region included the
foot, the lower leg and the upper leg. It was separated from the
trunk by an inclined line passing just below the pelvis, which
crossed the neck of the femur. The trunk region included the
entire body except the arms, legs and head regions. The head
region comprised all skeletal parts of the skull and cervical ver-
tebra above a horizontal line passing just below the jawbone.
With this analysis, regional body fat and lean mass can be
assessed with a coefficient of variation below 5% (Calbet et al.,
1998).
Peripheral venous blood was collected from all subjects to
determine serum total CK activity, a widely used marker of
skeletal muscle damage (Sorichter et al., 1999). CK activity
was determined using a standard photometric analyzer (Hitachi
911, Boehringer Mannheim, Mannheim, Germany), at baseline
(under “resting” conditions, that is, after 24 or more hours
with physical activities restricted to the minimum) at the fol-
lowing time points: pre-training, before each strength assess-
ment (end of 1st, 2nd, 3rd and 4th month), and after detrain-
ing. Serum total CK activity was also measured 1 h after each
strength assessment (end of 1st, 2nd, 3rd and 4th month).
The mean baseline values in our laboratory for adult male and
female McArdle patients are 3,069 ± 2,356 and 1686.2 ± 1964.8
U·L−1, respectively, whereas the mean baseline values for healthy
aged-matched controls are 151 ± 48 and 97.7 ± 35.7 U·L−1,
respectively.
Identification of patient clinical features allowed us to allocate
them to one of the following clinical severity classes according to
the most commonly used phenotype severity scale (Martinuzzi
et al., 2003): “0 = asymptomatic or virtually asymptomatic (mild
exercise intolerance, but no functional limitation in any daily
life activity); 1 = exercise intolerance, contractures, myalgia, and
limitation of acute strenuous exercise, and occasionally in daily
life activities; no record of myoglobinuria, no muscle wasting or
weakness; 2 = same as 1, plus recurrent exertional myoglobinuria,
moderate restriction in exercise, and limitation in daily life activi-
ties; 3 = same as 2, plus fixed muscle weakness, with or without
wasting and severe limitations on exercise and most daily life
activities”.
STATISTICAL ANALYSIS
In order to decrease the risk of statistical type I error, we used
the nonparametric Friedman test (instead of a repeated-measures
ANOVA) to compare within subjects the mean values of all the
variables measured at the different time points. All statistical
tests were performed using the Social Sciences package (SPSS,
2010, IBM SPSS Statistics 19 Core System User’s Guide; SPSS
Inc., Chicago, IL). Also to avoid type I error, post hoc pairwise
comparisons were only performed when a significant time effect
was found. Significance was set at α = 0.05 and results are
expressed as means± standard error of the mean (SEM).
RESULTS
ADHERENCE AND SIDE EFFECTS
Adherence to training was 100% in 5 patients and 84% in the 2
remaining patients (with reasons for missing sessions being inde-
pendent from the training itself, i.e., viral respiratory infection
in 1 patient and household or children care tasks in the other
one). No major contraindication was noted during the training
or strength assessment sessions other than the usual muscle
discomfort and soreness associated with resistance exercise in
non-habituated people (especially during the initial sessions). We
only had to interrupt a given set of repetitions due to muscle
stiffness on 5 occasions (2 patients). No episode of myoglobinuria
(i.e., no occurrence of “dark urine”) was reported, which is
consistent with the fact that serum CK activity levels showed no
major increases above the reference limits for this population (see
below).
The training program had a significant impact on total and
lower extremities’ lean mass (P < 0.05 for the time effect), with
mean values increasing with training and decreasing with detrain-
ing (Table 2). In contrast, body fat mass remained essentially
unchanged (P > 0.05). The increase in total or lower extremities’
lean mass from pre- to post-training averaged +855 g (95%
confidence interval (CI): 30, 1679) and +547 g (95% CI: 116,
978), respectively, with all patients showing an increase with
training, except one patient (i.e., patient B, 33 years, severity
class 3). Detraining resulted in a significant decrease in total
(−1,222 g (95%CI: −2,585, 340)) and lower extremities’ lean
mass compared to post-training (−521 g (95%CI:−846,−197)).
Detraining values of total and lower extremities’ lean mass were
not significantly different from pre-training values.
The results of upper body (bench press) or lower body muscle
strength (half-squat), expressed as the highest value of average
muscle power (W, Figure 2) or force (N) in the concentric-
propulsive phase of repetitions (Figure 3), or as the load (kg)
eliciting such values (Figure 4), showed the following overall
pattern: consistent increase (e.g., bench press: +52 W (95% CI:
13, 91): half-squat: +173 W (95% CI: 96, 251)) over the 4-month
training period (such that post-training values were significantly
higher than pre-training values), and a decline after detrain-
ing. Detraining resulted in a significant loss compared to post-
training, but strength after detraining was still significantly greater
than at pre-training. Importantly, all the participants, with no
exception, showed a clear gain in muscle strength after the 4-
month training period.
No significant time effect (P > 0.05) was noted for baseline or
post-strength assessment values of serum CK activity (Figure 5),
which remained essentially within the range values reported in
our laboratory for McArdle patients (and well below the upper
limit value of 95% CI (3,387 U·L−1)), indicating that the training
program did not induce major increases in CK-emia. Further,
an increasing trend in CK levels was noted in the 1st month of
training that was reversed thereafter, which reflected a positive
adaptation to the program.
The clinical course of the disease is shown in Figure 6. All
patients changed to a lower severity class with training, such that
none of them belonged to the highest disease severity category
(class 3) after training and, as such, did not have fixed muscle
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FIGURE 2 | Results (mean ± SEM) of upper body (bench press) and
lower body muscle strength (half-squat) expressed as highest value of
average muscle power in the concentric-propulsive repetition phase.
Significant differences between time points are indicated by brackets. Of
note, due to the high number of time points during the training period, and
thus to minimize type I error, pairwise post hoc comparisons of pre vs.
post-training were only performed at the end (4th month) of the training
period.
FIGURE 3 | Results (mean ± SEM) of upper body (bench press) and
lower body muscle strength (half-squat) expressed as highest value of
muscle force (N) in the concentric-propulsive repetition phase.
Significant differences between time points are indicated by brackets. Of
note, due to the high number of time points during the training period, and
thus to minimize type I error, pairwise post hoc comparisons of pre- vs.
post-training were only performed at the end (4th month) of the training
period.
weakness anymore. Further, 2 patients moved to class 0, which
is essentially symptom-free. Most of the clinical improvements
FIGURE 4 | Results (mean ± SEM) of upper body (bench press) or
lower body muscle strength (half-squat) expressed as the load
eliciting the highest value of average muscle power in the
concentric-propulsive repetition phase. Significant differences between
time points are indicated by brackets. Of note, due to the high number of
time points during the training period, and thus to minimize type I error,
pairwise post hoc comparisons of pre- vs. post-training were only
performed at the end (4th month) of the training period.
FIGURE 5 | Results (mean ± SEM) of serum creatine kinase (CK)
activity assessed at baseline (resting conditions) and 1 h after the
strength tests. No significant time effect (P > 0.05) was noted for baseline
or post-strength assessment values.
(except for one patient) were retained at detraining, that is, all
patients were classed as class 1 for disease severity.
DISCUSSION
The main, novel findings of our study were threefold. First, the
training program was feasible, free of noticeable adverse effects
(with no episode of myoglobinuria and with CK-emia remaining
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FIGURE 6 | Patients’ individual scores of disease severity using the
scale by Martinuzzi et al (Martinuzzi et al., 2003): “class
0 = asymptomatic or virtually asymptomatic (mild exercise
intolerance, but no functional limitation in any daily life activity);
1 = exercise intolerance, contractures, myalgia, and limitation of acute
strenuous exercise, and occasionally in daily life activities; no record of
myoglobinuria, no muscle wasting or weakness; 2 = same as 1, plus
recurrent exertional myoglobinuria, moderate restriction in exercise,
and limitation in daily life activities; 3 = same as 2, plus fixed muscle
weakness, with or without wasting and severe limitations on exercise
and most daily life activities”.
within safe limits) and well tolerated by the patients. This is
especially relevant when considering that ∼60% of them origi-
nally belonged to the highest severity class and thus had fixed
muscle weakness and limitations during daily living activities such
as house-hold tasks. Second, the training program significantly
increased total and lower extremities’ lean mass, with all the
patients except one showing an improvement in these variables.
This increase in lean mass was reflected in the consistent increase
(>twofold) of upper and lower body strength over the 4-month
training period, with all the patients showing an improvement.
Importantly, training-induced gains were not totally lost with
detraining. Finally, the program had direct clinical benefits,
because clinical severity decreased with training. Notably, after
training, all the patients moved to severity classes 0–1, that is,
they became virtually asymptomatic (class 0) or at most had
occasional limitations in daily life activities (class 1). In addition,
the improvements in clinical course were essentially retained at
detraining, which is consistent with the fact that previous gains in
muscle strength were not completely lost after detraining. To date,
we are not aware of any therapeutic intervention showing such
practical benefits in McArdle patients, and arguably of any other
lifestyle intervention able to induce such clinical improvement
in genetic neuromuscular disorders. No significant beneficial
effects have been reported in McArdle patients receiving branched
chain amino acids (MacLean et al., 1998), depot glucagon (Day
and Mastaglia, 1985), dantrolene sodium (Poels et al., 1990),
verapamil (Lane et al., 1986), vitamin B6 (Phoenix et al., 1998)
(except in one recent case report (Sato et al., 2012)), or high-
dose oral ribose (Steele et al., 1996). More controversial are the
effects of creatine supplementation: low-dose supplementation
(60 mg.kg−1.day−1 for 4 weeks) attenuated muscle complaints
in 5 out of the 9 McArdle patients (Vorgerd et al., 2000) but
higher doses (150 mg.kg−1.day−1) actually exacerbated exercise-
induced myalgia for unknown reasons (Vorgerd et al., 2002).
A 12-week treatment with the angiotensin converting enzyme
(ACE) inhibitor ramipril (2.5 mg.day−1) attenuated disability
in McArdle patients, but the effect was more marked in those
harboring the D/D genotype of the insertion(I)/deletion(D) poly-
morphism in the ACE gene (Martinuzzi et al., 2008). A short-
term trial (10 days) with a “read through” compound able to
synthesize full proteins from transcripts containing premature
termination stop codons (i.e., gentamicin) failed to normalize 31P
magnetic resonance spectroscopy indicators of myophosphorylase
deficiency in the muscle of McArdle patients (Schroers et al.,
2006).
This is the first report on the feasibility and functional and
clinical effects of a resistance training program in adult McArdle
patients. The data are novel and we believe that assessing the
applicability of this type of program in adults with McArdle
disease is of medical interest because this type of exercise should
form part of the routine exercise prescription to maintain and
improve health and functional status in most, if not all population
groups (Garber et al., 2011). Resistance training is also gaining
growing attention for its effectiveness in attenuating aging sar-
copenia as well as the status of muscle weakness and atrophy that
accompanies most chronic conditions, such as neuromuscular
disorders (Sanchis-Gomar et al., 2014). This is an important
consideration also in McArdle disease because the baseline val-
ues of muscle mass and strength of the study participants were
quite low compared to the general population. For instance, the
mean total lean mass (∼42 kg) of the 5 female patients (age
range: 34–48 years) at the start of the program, was only ∼6%
higher than the values recently reported in old, sedentary Spanish
women (mean age 75 years) (Gómez-Cabello et al., 2013a), and
the values of upper body lean mass were even lower (∼−11%)
in the same McArdle patients compared to the old sedentary
Spanish women (Gómez-Cabello et al., 2013b). The latter finding
is consistent with the fact that 4 of the female patients had
fixed muscle weakness affecting mostly proximal muscles. As for
the muscle strength values, recent research with the same test
and equipment for strength assessment used here showed that
young male adults with a mean age comparable to that of the 2
studied male patients had average values of peak power during
the bench press test (at 30 kg) of ∼320 W (vs. only 140–188 W
at the same load in our male patients) (Sanchez-Medina et al.,
2010).
Concerns are frequently raised by clinicians as to the poten-
tial risks of exercise, particularly weight lifting, in McArdle
patients. However, serum CK activity did not increase with
resistance training (and in fact tended to decrease with training
after the 1st month, indicating a good muscle tissue adapta-
tion to the program) and we recorded no incidence of myo-
globinuria. This indicates that the weight training program was
well tolerated. On the other hand, it must be kept in mind
that muscle damage, or at least some degree of it, as indi-
cated by high serum CK activity, is a necessary physiological
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stimulus for muscle to be repaired and adaptative hypertro-
phy to occur (Clarkson and Hubal, 2002). Our results are
consistent with those of a previous case report study from
our laboratory showing the functional benefits of resistance
training in an adolescent with McArdle disease (García-Benítez
et al., 2013). Muscle mass was not measured in this case study
and thus it could not be determined to what extent muscle
strength gains were due to neuromuscular adaptations only
or to the occurrence of some degree of muscle hypertrophy,
whereas here we showed that exercise-induced hypertrophy is
an attainable goal in McArdle patients. The finding that both
muscle mass and strength increased in these patients is of
clinical relevance because low muscle mass and poor mus-
cle strength are highly prevalent among westerners and are
important risk factors for disability and potentially mortal-
ity in individuals as they age (especially if combined with
high adiposity), whereas high muscle mass and strength are
associated with a healthier cardiometabolic phenotype (Kalyani
et al., 2012). With regards to this, besides the problem of the
low muscle mass/strength levels shown here, recent research
from our group has indicated that McArdle patients have an
overall unfavorable cardiometabolic profile (Munguía-Izquierdo
et al., 2014). On the other hand, the fact that gains in mus-
cle strength were not totally lost after detraining is in over-
all agreement with previous research in healthy adults (Mujika
and Padilla, 2001) or in chronic disease populations (Herrero
et al., 2006) showing that, at least compared to muscle oxida-
tive capacity, muscular strength suffers a more limited decrease
after relatively short periods of detraining. This phenomenon
is due, at least partly, to the fact that gains in neuromus-
cular performance (i.e., motor unit recruitment) can be rela-
tively retained during periods of detraining (Mujika and Padilla,
2001).
Our study is not without limitations. First, we did not assess
a control group of McArdle patients receiving no exercise inter-
vention, although the quasi-experimental design we used (where
each subject acted as their own control) might overcome, at
least partly, this limitation. It would have been interesting to
compare the effects of the present resistance intervention with
other types of exercise programs (e.g., stair climbing, brisk walk-
ing) in McArdle patients. On the other hand, assessing healthy
controls performing the same weight training intervention might
had allowed us to determine if the ability to gain muscle mass
and strength is limited (or not) in McArdle patients compared
to non-patients. Finally, further research might determine if
adding protein or creatine supplements to the current training
program might contribute to maximize the gains in patients’
muscle mass.
In summary, if appropriate training guidelines are followed
(i.e., qualified instruction, competent supervision, and appropri-
ate progression of the volume and intensity of training as we did
here), regular participation in a strength training program has
the potential to improve the muscle strength and mass, as well
as the clinical status, of McArdle patients. While keeping in mind
the need for large sample intervention studies (which might not
be easily feasible in rare diseases as this one), our preliminary
data suggest that supervised resistance training is feasible in
McArdle patients and has medical benefits, i.e., increased muscle
strength and force and attenuation of clinical severity. Thus, we
believe that the statement that “exercise is medicine” also applies
to a disease which has been traditionally considered to be the
paradigm of exercise intolerance, especially with regard to weight
lifting.
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